(Alliance News) - Verona Pharma PLC on Wednesday said it has initiated the multiple dose part of its phase 2 clinical trial to evaluate the pressurized metered-dose inhaler formulation.
The biopharmaceutical company focused on respiratory diseases said it will evaluate the formulation of ensifentrine's performance in patients with moderate-to-severe chronic obstructive pulmonary disease, or COPD.
This comes after postponements of the trial due to Covid-19 earlier in the year.
The first part of the phase saw 40 patients given a single dose of the formulation and led to promising results, with lung function increasing in those given the formulation.
The next part of phase 2 will see approximately 30 moderate to severe COPD patients given doses twice daily over one week.
Results are expected in the first half of next year.
Chief Executive David Zaccardelli said: “We are pleased to start the multiple dose part of this pMDI study and expect the results in the first half of 2021. Data from the single dose part of this pMDI study are very encouraging and consistent with data from Phase 2 clinical trials with our nebulized and dry powder inhaler formulations of ensifentrine.
Verona Pharma shares were up 3.0% at 85.00 pence each on Wednesday morning in London.
By Greg Roxburgh; gregroxburgh@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
